NCT06863376RecruitingPhase 2
Evaluating the Safety and Efficacy of Carbocisteine in the Treatment of Nonalcoholic Fatty Liver Disease Patients
Source: ClinicalTrials.gov · Last updated 4 May 2026
Brief summary (registry, in English)
Nonalcoholic fatty liver disease (NAFLD) is a global public health concern, and the leading cause of chronic liver disease, especially in developed countries. NAFLD is characterized by lipid accumulation in the liver not attributed to other causes. Lifestyle interventions, including dietary modification and exercise, remain the cornerstone of NAFLD treatment. Pharmacological treatments aimed primarily at improving liver disease should generally be limited to those with biopsy-proven NASH and fibrosis.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 46 (estimated)
- First submitted
- 1 Mar 2025
- Start date
- Mar 2025
- Primary completion date
- Mar 2027
- Lead sponsor
- Tanta University
- Diseases
- Fatty liver disease (MASLD/MASH)
- NCT number
- NCT06863376
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 46
- From Mar 2025 to the primary completion date, Mar 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Other etiology of chronic liver diseases such as viral hepatitis, drug-induced hepatitis, autoimmune hepatitis.
- patients suffering from chronic kidney disease, and hyper/hypoparathyroidism
- Hypersensitivity to carbocistiene.
Other
- Pregnant and/or lactating women
- Excessive alcohol use (defined as an average alcohol intake \> 30 g per day in men and \> 20 g per day in women)
Who the study is looking for
- Either male or female adult patients (\>18 years) with fatty liver diagnosis by using upper abdominal ultrasound echography
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tanta Unuversity Coordinator of this site? Confirm its status | Tanta | Egypt | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.